Drug intelligence / Profile preview

FCN-016

Development stage: Unknown
Lead developer: Chongqing Fuchuang Pharmaceutical Research
Modality: Small Molecules
Administration: Ophthalmic

Overview

FCN-016 is a small molecule Rho-associated protein kinase (ROCK) inhibitor developed by Fosun Pharma USA for the treatment of glaucoma. By inhibiting ROCK, the drug modulates the actin cytoskeleton within the trabecular meshwork, which enhances the outflow of aqueous humor and leads to a reduction in intraocular pressure. It is currently being evaluated in Phase 1 clinical trials.

Targets

ROCK1 (Rho-associated coiled-coil containing protein kinase 1)

Beyond the preview

Go deeper on FCN-016.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FCN-016.

Explore the full profile